Medical Home»Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown - FierceBiotech

Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown - FierceBiotech

Share  Email
Date : 4th-Sep-2014 06:02:03 AM
Title : Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown - FierceBiotech

Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown
FierceBiotech
Beating Lantus has been a big focus in diabetes drug development, a game of one upmanship as the world's dominant players in the field jockey for a better position in the fast-growing megablockbuster drug market. Eli Lilly, though, which has had to cut ...
Lilly's diabetes drug trumps Sanofi's in late-stage trialsReuters
Lilly says insulin fares well in late-stage testsBellingham Herald


more...<< Back

Other Recent NewsFeed

As of 05:01:00 PM PST
Lessons learned from genetic testing for channelopathies Genetic testing has become routine for many inherited disorders and is rapidly emerging as the standard of care in some circumstances, including rare disorders affecting the nervous system. Next-gener... More | Save |  Share  Email
Chronic kidney disease and stroke We appreciate the idea of cerebrorenal interaction, as proposed by Toyoda and colleagues in their recent Review, because it raises an important clinical issue with respect to chronic kidney disease in... More | Save |  Share  Email
CGRP as a new target in prevention and treatment of migraine Calcitonin-gene-related peptide (CGRP), which is released during migraine attacks, has been identified as a possible target for the treatment of migraine. CGRP is located in sensory nerve endings in c... More | Save |  Share  Email
Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Amyotrophic lateral sclerosis (ALS) is one of the most rapidly progressive neurodegenerative diseases of unknown cause. Riluzole is the only drug that slows disease progression. More than 50 randomise... More | Save |  Share  Email
View All...

 
Subscribe
x